Pricing Log in Create free account

BridgeBio Oncology Therapeutics, Inc (BBOT) vs Upstream Bio, Inc. (UPB)

BridgeBio Oncology Therapeutics, Inc and Upstream Bio, Inc. are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Upstream Bio, Inc. are of similar size ($176.9M and $163.6M). BridgeBio Oncology Therapeutics, Inc has the higher net margin (0.00% vs −4,955.7%) and the higher return on invested capital (−127.7% vs −1,100.9%). Across the 13 metrics below, BridgeBio Oncology Therapeutics, Inc leads on 7 and Upstream Bio, Inc. on 6.

Valuation

Metric BBOT UPB Biotechnology median
P/E n/m n/m 10.60
P/S n/m 55.81 9.40
P/B 0.51 0.65 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.31 0.50 0.66
EV/Sales n/m (26.93) 9.02
Earnings yield (135.29%) (89.78%) (32.88%)
Free cash flow yield (92.81%) (77.55%) (23.13%)

Profitability

Metric BBOT UPB Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (5,382.65%) 0.00%
Net margin 0.00% (4,955.67%) 0.00%
Free cash flow margin 0.00% (4,317.42%) 0.00%
Return on equity (252.10%) (46.05%) (51.96%)
Return on assets (96.69%) (44.61%) (46.06%)
Return on invested capital (127.66%) (1,100.93%) 0.00%

Growth

Metric BBOT UPB Biotechnology median
Revenue growth (TTM) — 15.98% 6.76%
EPS growth (last fiscal year) 99.93% 52.33% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric BBOT UPB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 27.99 4.97
Net debt to EBITDA 2.93 2.11 1.01

Dividend

Metric BBOT UPB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BBOT UPB Biotechnology median
Market cap 163.56m 176.91m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack